Ars Pharmaceuticals, INC

ARS Pharmaceuticals announced the resignation of a board director and the departure of its Chief Medical Officer, effective July 15, 2026, with associated severance payments.

ARS Pharmaceuticals announces immediate CEO transition with Donn Casale appointed as Chief Executive Officer, replacing Richard Lowenthal.

ARS Pharmaceuticals stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP.

ARS Pharmaceuticals announced first quarter 2026 financial results, highlighting $22.7 million in total revenue and providing updates on neffy's commercialization, including progress with CVS Caremark and international approvals.

ARS Pharmaceuticals announced the appointment of Donn Casale as President, effective June 1, 2026, with a compensation package including a $575,000 base salary and a significant stock option grant.

ARS Pharmaceuticals reported robust third-quarter 2025 financial results, driven by significant neffy U.S. net product revenue and strong commercial launch progress, supported by a substantial cash position.

ARS Pharmaceuticals announced a significant increase in total revenue for the first quarter of 2026, driven by strong product sales of neffy and contributions from collaboration and supply agreements.

ARS Pharmaceuticals reports a significant increase in neffy product revenue and secured a $100 million term loan, but also saw a substantial rise in net loss and operating expenses for Q3 2025.

ARS Pharmaceuticals reports significant revenue growth from its needle-free epinephrine product, neffy, following its U.S. and EU commercial launches, despite increased operating losses due to aggressive market expansion.

ARS Pharmaceuticals reports its first quarter 2025 financial results, highlighting the ongoing commercial launch of Neffy and providing updates on regulatory and clinical developments.

ARS Pharmaceuticals has filed an amendment to its quarterly report to disclose changes in Rule 10b5-1 trading plans by an executive officer and a board member.

ARS Pharmaceuticals initiated the commercial launch of Neffy in the U.S. and secured a significant European partnership with ALK, while reporting a net loss of $41.9 million for the first nine months of 2024.

ARS Pharmaceuticals highlights the FDA and European Commission approval and commercial launch of Neffy, along with strategic partnerships to expand its global reach.

ARS Pharmaceuticals' 10-K filing details the company's progress in developing Neffy, a needle-free epinephrine nasal spray, and its plans for commercialization.

RA Capital Management, L.P. and affiliated entities report the acquisition of a stock option for 30,000 shares of ARS Pharmaceuticals, Inc. (SPRY) with an exercise price of $10.54.

ARS Pharmaceuticals, Inc. reports that Director Rajeev Dadoo acquired 30,000 stock options on June 24, 2026, as detailed in a Form 4 filing.

ARS Pharmaceuticals, Inc. Director Pratik Shah acquired 30,000 stock options with an exercise price of $10.54.

ARS Pharmaceuticals, Inc. director Michael Kelly acquired 30,000 stock options with an exercise price of $10.54, vesting in full on June 24, 2027, or the 2027 annual meeting.

ARS Pharmaceuticals, Inc. reports that Director Saqib Islam acquired 30,000 stock options on June 24, 2026.

Peter A. Thompson, a Director at ARS Pharmaceuticals, Inc., acquired 30,000 stock options with an exercise price of $10.54.

ARS Pharmaceuticals announces its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and provides an update on the successful commercial launch of its needle-free epinephrine nasal spray, neffy.

ARS Pharmaceuticals, Inc. has filed a definitive proxy statement with the SEC.

ARS Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held virtually on June 25, 2025, to elect directors and ratify the selection of its independent accounting firm.

ARS Pharmaceuticals has filed a definitive proxy statement with the Securities and Exchange Commission.

ARS Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors and ratify the selection of Ernst & Young LLP as its independent accounting firm.

ARS Pharmaceuticals, Inc. has entered into a credit agreement for up to $250 million in term loans with RA Capital affiliates and OMERS Administration Corporation to fund product development and general corporate purposes.

Deerfield Management and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 7.75% through recent open market sales.

Deerfield Private Design Funds have substantially decreased their beneficial ownership in ARS Pharmaceuticals, Inc. through a series of open market sales in July 2025.

Deerfield Management Company and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 9.90% of common stock through recent open market sales.

Deerfield Management Company, L.P. and its affiliated funds, along with James E. Flynn, have filed an Amendment No. 2 to Schedule 13D, reporting a collective beneficial ownership of 10.72% of ARS Pharmaceuticals, Inc.'s common stock.

Several entities affiliated with Millennium Management have jointly filed a Schedule 13G, reporting beneficial ownership of ARS Pharmaceuticals common stock.

Millennium Management LLC and affiliated entities have reported a 6.0% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.4% passive beneficial ownership stake in ARS Pharmaceuticals, Inc.

Rubric Capital Management LP and David Rosen have reported a 6.27% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock as of December 31, 2025.